Bio-Path’s (BPTH) Buy Rating Reiterated at HC Wainwright

Share on StockTwits

HC Wainwright reissued their buy rating on shares of Bio-Path (NASDAQ:BPTH) in a research note released on Monday, Stock Target Advisor reports. HC Wainwright currently has a $28.00 price objective on the stock.

Separately, ValuEngine lowered Bio-Path from a hold rating to a sell rating in a report on Friday, October 25th.

BPTH stock opened at $9.80 on Monday. The company has a current ratio of 13.85, a quick ratio of 13.85 and a debt-to-equity ratio of 0.02. Bio-Path has a 1 year low of $1.61 and a 1 year high of $73.52. The company has a fifty day simple moving average of $10.67 and a 200 day simple moving average of $12.58. The firm has a market cap of $30.75 million, a PE ratio of -0.68 and a beta of 3.14.

Hedge funds and other institutional investors have recently modified their holdings of the company. Morgan Stanley raised its stake in shares of Bio-Path by 19,858.0% in the 2nd quarter. Morgan Stanley now owns 19,958 shares of the company’s stock valued at $267,000 after acquiring an additional 19,858 shares in the last quarter. Vanguard Group Inc. boosted its position in Bio-Path by 10.3% during the second quarter. Vanguard Group Inc. now owns 27,925 shares of the company’s stock worth $374,000 after purchasing an additional 2,601 shares during the period. Finally, BlackRock Inc. boosted its position in Bio-Path by 17.5% during the second quarter. BlackRock Inc. now owns 46,879 shares of the company’s stock worth $628,000 after purchasing an additional 6,978 shares during the period. 9.43% of the stock is currently owned by institutional investors and hedge funds.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

See Also: What is a Call Option?

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ferroglobe  Trading 10.9% Higher  After Earnings Beat
Ferroglobe Trading 10.9% Higher After Earnings Beat
Plair Price Down 28.1% This Week
Plair Price Down 28.1% This Week
Consensus Tops 1-Day Volume of $191.00
Consensus Tops 1-Day Volume of $191.00
Brokerages Set Zumiez Inc.  Target Price at $28.43
Brokerages Set Zumiez Inc. Target Price at $28.43
Mastercard  Receiving Neutral Press Coverage, Report Shows
Mastercard Receiving Neutral Press Coverage, Report Shows
Ryo Currency  Trading 21.3% Higher  Over Last Week
Ryo Currency Trading 21.3% Higher Over Last Week


© 2006-2019 Ticker Report